Can You Start Empagliflozin (Jardiance) for HFpEF with Iron-Deficiency Anemia?
Yes, you should start empagliflozin 10 mg daily for your heart failure with preserved ejection fraction, as it is now a cornerstone therapy for HFpEF regardless of diabetes status, and your eGFR ≥20 mL/min/1.73 m² meets the initiation threshold. 1, 2
Evidence-Based Rationale
SGLT2 Inhibitors Are Now Guideline-Directed Medical Therapy for HFpEF
Empagliflozin received a Class 1 (strong) recommendation from the 2022 AHA/ACC/HFSA guidelines for patients with HFpEF (LVEF ≥50%) to reduce hospitalizations and cardiovascular death. 1
The 2023 ACC Expert Consensus similarly endorses empagliflozin as first-line GDMT for HFpEF, based on the EMPEROR-Preserved trial showing a 21% reduction in the composite endpoint of HF hospitalization or cardiovascular death (HR 0.79,95% CI 0.69–0.90). 1
This benefit was consistent regardless of diabetes status: HR 0.79 in patients with diabetes vs. HR 0.78 in those without (P-interaction = 0.92). 3
Your Renal Function Supports Initiation
KDIGO 2022 guidelines strongly recommend (Grade 1A) initiating empagliflozin in adults with heart failure and eGFR ≥20 mL/min/1.73 m², regardless of albuminuria or diabetes. 2
The FDA label and heart failure trials (EMPEROR-Reduced and EMPEROR-Preserved) enrolled patients with eGFR as low as 20 mL/min/1.73 m², demonstrating safety and efficacy in this range. 4
No dose adjustment is required for eGFR ≥20 mL/min/1.73 m²; the standard 10 mg daily dose is appropriate. 2, 4
Iron-Deficiency Anemia Does Not Contraindicate Empagliflozin
There is no contraindication or interaction between empagliflozin and iron-deficiency anemia. 4
In fact, iron deficiency is common in HFpEF and should be assessed and treated independently (intravenous iron if indicated), but does not preclude SGLT2 inhibitor therapy. 1
Compatibility with Your Current Regimen
Empagliflozin is safe and effective when added to background therapy including diuretics, ACE inhibitors/ARBs/ARNIs, and mineralocorticoid receptor antagonists (MRAs). 1
In EMPEROR-Preserved, 37.5% of patients were on MRAs at baseline, and empagliflozin reduced the primary outcome in both MRA users (HR 0.87) and non-users (HR 0.73), with no significant interaction (P = 0.22). 5
Empagliflozin reduced hyperkalemia risk regardless of MRA use (HR 0.74 in MRA users, P-interaction = 0.29), which is particularly relevant given your concurrent MRA therapy. 5
Practical Implementation
Dosing and Monitoring
Start empagliflozin 10 mg once daily in the morning, with or without food. 2, 4
Expect a transient eGFR dip of 2–6% (≈2 mL/min/1.73 m²) within the first 2 months; this is hemodynamic, reversible, and should not trigger discontinuation unless creatinine rises >30% from baseline. 2
Continue routine CKD monitoring; no additional eGFR checks are required solely because empagliflozin was started. 2
Assess volume status and blood pressure at follow-up visits, especially in the first few weeks, as empagliflozin has mild diuretic effects. 2, 4
Safety Considerations
Volume depletion risk is low even at lower eGFR, but consider reducing your diuretic dose if you develop symptomatic hypotension or signs of hypovolemia. 2, 4
Genital mycotic infections occur in ≈6% of patients (vs. 1% with placebo); counsel on genital hygiene. 2
Withhold empagliflozin during prolonged fasting, surgery, or critical illness to reduce the rare risk of euglycemic diabetic ketoacidosis (which can occur even with blood glucose <250 mg/dL). 2
Hypoglycemia risk is minimal at your eGFR level, as glucose-lowering efficacy wanes with declining renal function; no preemptive adjustment of other glucose-lowering agents is needed unless hypoglycemia occurs. 2, 4
Continuation Principle
Once started, continue empagliflozin even if eGFR falls below 20 mL/min/1.73 m², unless the drug is not tolerated or you initiate dialysis. 2
Empagliflozin is contraindicated only in patients on dialysis. 4
Expected Benefits
Cardiovascular Outcomes
Empagliflozin reduces HF hospitalizations by ≈30% across the ejection fraction spectrum from <25% to <65%, with an attenuated effect only in patients with LVEF ≥65%. 6
In EMPEROR-Preserved, empagliflozin reduced first HF hospitalization (HR 0.71,95% CI 0.60–0.83) and total (first and recurrent) HF hospitalizations (HR 0.73,95% CI 0.61–0.88). 1
Renal Protection
Empagliflozin slows eGFR decline by 1.11 mL/min/1.73 m²/year in patients with CKD and by 2.41 mL/min/1.73 m²/year in those without CKD. 7
The composite kidney outcome (sustained profound eGFR decline, chronic dialysis, or transplant) was reduced by 47% in patients without CKD (HR 0.53) and by 54% in those with CKD (HR 0.46). 7
Quality of Life
- Empagliflozin significantly improved Kansas City Cardiomyopathy Questionnaire (KCCQ) scores at 52 weeks, indicating better symptom burden and functional capacity. 1
Common Pitfalls to Avoid
Do not discontinue empagliflozin for the expected acute eGFR dip unless creatinine rises >30% from baseline. 2
Do not withhold initiation based solely on low albuminuria; benefits extend to patients with minimal albuminuria. 2
Do not stop empagliflozin when eGFR falls below 20 mL/min/1.73 m² if you are already on therapy. 2
Do not rely on outdated FDA labeling that restricts use below eGFR 45 mL/min/1.73 m² for glycemic control; current evidence supports use down to eGFR 20 for heart failure and renal protection. 2, 4
Pause empagliflozin during acute illness, surgery, or prolonged fasting to lower ketoacidosis risk. 2